Switzerland· 52780001
Glycophos, Konzentrat zur Herstellung einer Infusionslösung
A sodium glycerophosphate product containing natrii glycerophosphas, phosphas, natrium, registered in Switzerland by Fresenius Kabi (Schweiz) AG and dispensed under Swissmedic category B. The same ATC class is registered in 9 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Sodium glycerophosphate is registered in 9 of 19 countries.
Countries holding a registration under ATC B05XA14 (sodium glycerophosphate), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 6 of them publish a price we can compare per daily dose
Sodium glycerophosphate · ATC B05XA14
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
The record
At a glance
Swissmedic (Switzerland)- Active substance
- natrii glycerophosphas, phosphas, natrium
- Manufacturer
- Fresenius Kabi (Schweiz) AG
- Country
- Switzerland (CH)
- ATC code
- B05XA14
- ATC class
- Sodium glycerophosphate
- Swissmedic category
- B
- Reimbursed
- No
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
2 interactions on record for sodium glycerophosphate.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Sodium glycerophosphate · interactions on record
2 records
- 2 severe
Most severe, free to view
- ErdafitinibL01EN01severe
- ErdafitinibL01EX16severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under B05XA14
Sodium glycerophosphate, as other registers publish it.
- FinlandGlycophosFresenius Kabi AB
- DenmarkGlycophosFresenius Kabi AB
- FinlandGlycophosOrifarm Oy
- NorwayGlycophosFresenius Kabi
- PolandGlycophosInPharm Sp. z o.o.
- BelgiumGlycophos 20 mlFresenius Kabi
- BelgiumGlycophos 20 mlFresenius Kabi
- United KingdomGlycophos 4.32g/20ml concentrate for solution for infusion vialsFresenius Kabi Ltd
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9e4101ea-a5a6-4380-8672-725470058f42 GET /v1/drugs/9e4101ea-a5a6-4380-8672-725470058f42?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "swissmedic_auth",
"heilmittelcode": "Synthetika"
}See everything about sodium glycerophosphate.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.